Melanoma: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• PD-1 54
• BRAF 18
• PD-L1 21
• MEK 7
• TP53 0
• CTLA-4 10
• MAPK 2
• NRAS 8
• STING 0
• STAT3 0
• PRAME 3
• AKT 0
• PI3K 0
• BAP1 2
• VEGF 4
• mTOR 0
• ERK 0
• LAG-3 2
• RAS 2
• CTNNB1 0
• CD40 0
• CDKN2A 3
• TNF 0
• YAP 0
• PTEN 1
• JAK 0
• KIT 3
• KRAS 1
• JNK 0
• PPAR 0
• TIGIT 0
• ALK 0
• B7-H3 3
• BCL-2 0
• EZH2 0
• HIF-1 0
• IL-15 1
• NF1 2
• NLRP3 0
• NRF2 0
• AMPK 0
• HSP90 0
• CD47 0
• MYC 0
• PKM2 0
• AXL 1
• COX-2 0
• EGFR 0
• GPX4 0
• MET 1
• HDAC 1
• IDH 1
• IL-17 1
• MMP-9 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• HER2 3
• IGF1R 0
• PSMA 3

24 of 59+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Validation of artificial intelligence-based minibinders and inhibitors of Midkine in immune resistant tumours (MDK_MINIBINDERS)

  Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii· Madrid, Spain· EU contribution €150,000· until Apr 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Light-triggered Ultra-precise Carbon-enhanced phycocyanin Engineered Needles for Therapy (LUCENT)

  Univerzita Palackeho V Olomouci· Olomouc, Czechia· EU contribution €191,918· until Aug 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeted therapy to block melanoma progression through peptide phage-display profiling of melanoma cells and derived extracellular vesicles (Target-MelaneX)

  I3s - Instituto de Investigacao e Inovacao Em Saude Da Universidade Do Porto· Porto, Portugal· EU contribution €207,183· until Aug 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  THz-FIR Colour Imaging of Skin Condition Based on Analysis of Its Thermal Emission (THz-Skin)

  Ita-Suomen Yliopisto· Kuopio, Finland· EU contribution €2,998,913· until Jan 2030· 5 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Capturing UV Sunlight Using Hydrogen-Bond Networks: Organic Sun Screens for Skin Protection (CUSHOSP)

  United Nations Educational Scientific and Cultural Organization· Paris, France· EU contribution €150,000· until Jun 2027· 2 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 12 running projects, newest first. Listed amounts together: €11.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

  NCT04866810· National Cancer Institute (NCI)· Updated 19 Oct 2026

  “On hold pending planned interim analysis.”Registry text, quoted unchanged. Source

• Terminated

  A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

  NCT05529316· Agenus Inc.· Updated 19 Oct 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

  NCT03881488· Compass Therapeutics· Updated 9 Oct 2026

  “The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.”Registry text, quoted unchanged. Source

• Suspended

  Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

  NCT05264974· University of Florida· Updated 17 Sept 2026

  “seeking additional funding”Registry text, quoted unchanged. Source

• Terminated

  Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

  NCT05764395· Vanderbilt-Ingram Cancer Center· Updated 16 Sept 2026

  “Drug unavailable”Registry text, quoted unchanged. Source

• Terminated

  High Dose IL-2 in Combination With Anti-PD-1

  NCT03991130· Gregory Daniels· Updated 6 Aug 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Terminated

  Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists

  NCT03412058· UNICANCER· Updated 3 Aug 2026

  “The study was terminated prematurely due to insufficient patient recruitment”Registry text, quoted unchanged. Source

• Terminated

  Defining the Role of the Skin Microbiome in Immune-related Adverse Events

  NCT04734704· University Hospital, Bordeaux· Updated 23 Jun 2026

  “target number of patients not reached and disabling team changes”Registry text, quoted unchanged. Source

• Terminated

  Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

  NCT04955743· Yale University· Updated 4 Jun 2026

  “Lack of activity in the drugs”Registry text, quoted unchanged. Source

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Updated 4 Jun 2026

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

  NCT05155033· National Cancer Institute (NCI)· Source

• A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

  NCT06961006· Merck Sharp & Dohme LLC· Source

• A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

  NCT05608291· Regeneron Pharmaceuticals· Source

• A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

  NCT06066138· National Cancer Institute (NCI)· Source

• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  NCT06246916· Regeneron Pharmaceuticals· Source

• Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

  NCT07281924· University of Wisconsin, Madison· Source

• The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

  NCT04866810· National Cancer Institute (NCI)· Source

• Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

  NCT06784648· BioInvent International AB· Source

• A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

  NCT04835805· Genentech, Inc.· Source

• Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors

  NCT04140500· Hoffmann-La Roche· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 51
• Organoids 8
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 22
• Gene Expression Profiling 116
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 6
• Exome Sequencing 7
• Proteomics 47
• Metabolomics 20
• Mass Spectrometry 10
• Flow Cytometry 65
• Immunohistochemistry 106
• Liquid Biopsy 12
• Circulating Tumor DNA 37
• Xenograft Model Antitumor Assays 121
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 57
• Machine Learning 49
• Deep Learning 44
• Cohort Studies 78
• Genome-Wide Association Study 22

• Serum Peptidomic Profiling for Biomarker Discovery in Canine Oral Melanoma and Squamous Cell Carcinoma via MALDI-TOF and LC-MS/MS.

  Methods Mol Biol, Jan 2027

• Benchmarking cell segmentation in two Spatialomics platforms with open-source software.

  Sci Rep, Oct 2026

• Spatial and Single-Cell Multi-Omics Analyses of T-Cell Subsets and Interactions in Melanoma Lymph Node Metastasis.

  Exp Dermatol, Oct 2026

• Spatial Proteomics as a Potential Decision-Support Layer for Early Melanoma: A Narrative Review.

  Int J Dermatol, Oct 2026

• Melanoma Prognostication Using AI-Guided Histopathology.

  Int J Dermatol, Oct 2026

• Spatial Transcriptomic and Proteomic Analysis Identifies Novel Immune-Associated Biomarkers of Anti-PD1 Response in Metastatic Melanoma.

  Scand J Immunol, Oct 2026

• Integrated Genomic and Proteomic Analysis Reveals T-B Lymphocyte Signatures in the MYCN Driven "Immune Desert" of Specific Neuroblastoma Subtypes.

  CNS Neurosci Ther, Sept 2026

• Functional and Proteomic Profiles of CD3(+) Plasma-Derived Small Extracellular Vesicles Differentiate Cancer Patients From Healthy Donors.

  Eur J Immunol, Sept 2026

• Distinct molecular adaptations underlie convergent phenotypic responses to mannose in normal and metastatic melanocytes.

  Mol Cell Biochem, Aug 2026

• The promise of deep urine proteomics for diagnosis of cancer, neurologic, and metabolic diseases.

  PLoS One, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.